Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Casirivimab/imdevimab showed no clear difference in hospital discharge alive by day 30 compared with usual care alone (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom (100% reduction in seizure frequency) compared with usual care (very low certainty).
1 finding from 1 review
Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
Cognition and behaviour · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
Quality of life · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes quality of life compared with usual care (very low certainty).
1 finding from 1 review
Treatment withdrawal · children (aged 1 to 18 years) with drug‐resistant epilepsy
Ketogenic diet (KD) showed no clear difference in treatment withdrawal compared with usual care (low certainty).
1 finding from 1 review
Seizure freedom · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom compared with usual care (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes 50% or greater reduction in seizure frequency compared with usual care (very low certainty).
1 finding from 1 review
Adverse effects · adults (aged 16 years and over) with drug‐resistant epilepsy
1 finding from 1 review
Depression: mean scores at end of treatment (Analysis 1.4) · people with stroke
1 finding from 1 review
Psychological distress post‐treatment · people with stroke
1 finding from 1 review
General health · people with stroke
1 finding from 1 review
Social activities: mean scores at end of treatment (Analysis 2.10) · people with stroke
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review